Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Fort Worth, Texas

4 studies are recruiting for non-small cell lung cancer (nsclc) in Fort Worth, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Dallas Fort Worth, Fort Worth, Texas
    Locations
    20 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07277413 on ClinicalTrials.gov

  2. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The Center For Cancer And Blood Disorders, Fort Worth, Texas
    Locations
    259 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07361497 on ClinicalTrials.gov

  3. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

    IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants wi…

    Stage
    Phase 1
    Ages
    18 to 99
    Site
    START Dallas Fort Worth, LLC, Fort Worth, Texas
    Locations
    11 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07540572 on ClinicalTrials.gov

  4. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

    The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START Dallas, Fort Worth, Texas
    Locations
    3 in total
    Run by
    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT07517198 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.